Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies and diagnostics for Alzheimer’s disease and related neurodegenerative disorders. Headquartered in Austin, Texas, the company was originally founded as Pain Therapeutics in 1998 and rebranded to Cassava Sciences in 2017. Cassava’s research program centers on small molecules designed to address underlying mechanisms of neurodegeneration rather than solely targeting amyloid plaques or tau tangles.
The company’s lead drug candidate, simufilam (formerly PTI-125), is a proprietary small molecule that aims to restore normal shape and function to the scaffolding protein filamin A, which has been implicated in impaired neuronal signaling and inflammation in Alzheimer’s patients. Simufilam is being evaluated in Phase 2b and Phase 3 clinical trials, with studies conducted across multiple sites in the United States and Australia. Cassava also maintains a pipeline of diagnostics, including exploratory blood-based biomarkers intended to detect pathogenic hallmarks of Alzheimer’s disease at earlier stages.
Cassava Sciences is led by President and Chief Executive Officer Remi Barbier, who has guided the company’s strategic transition from pain management to neurodegenerative research. The executive team comprises professionals with backgrounds in neuroscience, clinical development, and regulatory affairs. Cassava’s board includes members with extensive experience in the biotechnology and pharmaceutical industries, supporting the company’s efforts to advance its pipeline and engage with regulatory authorities.
With a mission to transform the treatment and diagnosis of Alzheimer’s disease, Cassava Sciences collaborates with academic institutions and contract research organizations to conduct its clinical studies. While the company’s primary activities are centered in North America and Australia, it seeks to establish partnerships and expand its research footprint globally as it progresses its therapeutic and diagnostic programs toward regulatory approval.
AI Generated. May Contain Errors.
